Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder

Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–9.

Article  CAS  PubMed  Google Scholar 

Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–52.

Article  PubMed  PubMed Central  Google Scholar 

Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25(7):2089–98.

Article  PubMed  Google Scholar 

Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012;12(4):976–83.

Article  CAS  PubMed  Google Scholar 

Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15(10):2665–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732).

Francis A, Johnson DW, Teixeira-Pinto A, Craig JC, Wong G. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. Nephrol Dial Transplant. 2018;33(5):881–9.

Article  PubMed  Google Scholar 

Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–30.

Article  PubMed  Google Scholar 

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Opelz G, Naujokat C, Daniel V, Terness P, Dohler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227–33.

Article  CAS  PubMed  Google Scholar 

Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, et al. Risk Factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(1):53 e1-e10.

Article  PubMed  Google Scholar 

Salas MQ, Prem S, Remberger M, Lam W, Kim DDH, Michelis FV, et al. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma. 2020;61(13):3198–208.

Article  CAS  PubMed  Google Scholar 

Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asleh R, Clavell AL, Pereira NL, Smith B, Briasoulis A, Alnsasra H, et al. Incidence of malignancies in patients treated with sirolimus following heart transplantation. J Am Coll Cardiol. 2019;73(21):2676–88.

Article  CAS  PubMed  Google Scholar 

Kotton CN, Huprikar S, Kumar D. Transplant infectious diseases: a review of the Scientific Registry of Transplant Recipients Published Data. Am J Transplant. 2017;17(6):1439–46.

Article  CAS  PubMed  Google Scholar 

Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, et al. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematol Oncol. 2020;38(2):146–52.

Article  CAS  PubMed  Google Scholar 

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues: International agency for research on cancer Lyon; 2008.

Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, et al. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer. 2013;109(1):280–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, et al. Co-infection of cytomegalovirus and Epstein-Barr virus diminishes the frequency of CD56(dim)NKG2A(+)KIR(-) NK cells and contributes to suboptimal control of EBV in immunosuppressed children with post-transplant lymphoproliferative disorder. Front Immunol. 2020;11:1231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakid-Cordero C, Baron M, Guihot A, Vieillard V. Natural killer cells in post-transplant lymphoproliferative disorders. Cancers (Basel). 2021;13(8).

Nakid-Cordero C, Choquet S, Gauthier N, Balegroune N, Tarantino N, Morel V, et al. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2021;21(8):2846–63.

Article  CAS  PubMed  Google Scholar 

Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. Am J Clin Pathol. 2012;138(4):568–78.

Article  PubMed  Google Scholar 

Stubbins RJ, Mabilangan C, Rojas-Vasquez M, Lai RL, Zhu J, Preiksaitis JP, et al. Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes. Leuk Lymphoma. 2020;61(14):3319–30.

Article  PubMed  Google Scholar 

Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shestakova A, Grove N, Said J, Song S, Quintero-Rivera F. Trisomy 3, a sole recurrent cytogenetic abnormality in pediatric polymorphic post-transplant lymphoproliferative disorder (PTLD). Cancer Genet. 2020;248–249:39–48.

Article  PubMed  Google Scholar 

Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches. World J Transplant. 2020;10(2):29–46.

Article  PubMed  PubMed Central  Google Scholar 

Koff JL, Li JX, Zhang X, Switchenko JM, Flowers CR, Waller EK. Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer. 2018;124(11):2327–36.

Article  PubMed  Google Scholar 

Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, et al. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. 2016;7(25):37636–48.

Article  PubMed  PubMed Central  Google Scholar 

Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–83.

Article  PubMed  PubMed Central  Google Scholar 

Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13 Suppl 3:41–54 (quiz).

Article  CAS  PubMed  Google Scholar 

Jagadeesh D, Tsai DE, Wei W, Alvarez Bustamante J, Wagner-Johnston ND, Berg S, et al. Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplant (SOT): A multicenter real world analysis (RWA) of 877 patients (pts) treated in the modern era. American Society of Clinical Oncology; 2020. Analysis of large multi-instutional cohort of PTLD patients identifying prognostic factors.

Balfour HH Jr, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92.

Article  CAS  PubMed  Google Scholar 

Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75–82.

Article  CAS  PubMed  Google Scholar 

Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7(6):1648–55.

Article  CAS  PubMed  Google Scholar 

Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A. 1984;81(12):3806–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kapelushnik J, Ariad S, Benharroch D, Landau D, Moser A, Delsol G, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi’s sarcoma. Br J Haematol. 2001;113(2):425–8.

Article  CAS  PubMed 

留言 (0)

沒有登入
gif